Analyses of data from three studies provide insight into the use of Enbrela (etanercept) in the treatment of three conditions for which Enbrel is indicated: moderate-to-severe rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS).
These analyses, presented this week during the European League Against Rheumatism (EULAR) Annual Meeting in Copenhagen, add to the body of evidence that supports treatment with Enbrel for patients with these conditions.
Analyses from three separate trials of Enbrel – COMET, ASCEND and PRESTA showed that:
- The group of patients with early-active moderate-to-severe RA treated with Enbrel and methotrexate, who achieved and sustained a halt of progressive joint damage, maintained this level at two years, according to the COMET study
- In patients with AS (including those with and without peripheral joint involvement), Enbrel therapy significantly improved signs, symptoms, function, and mobility when compared to treatment with the DMARD sulfasalazine, according to the ASCEND study
- At step-down and usual doses, Enbrel provided significant improvement in joint symptoms compared to baseline in patients with active PsA in addition to achieving clearer skin, according to the PRESTA study
“Inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis significantly impact the daily lives of the patients who live with these conditions. These analyses support the role of etanercept therapy in the management of these diseases. The EULAR congress provides an important platform to present new information regarding ENBREL as a treatment option for patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis,” said Maxime Dougados, Professor of Rheumatology, René Descartes University Paris, France.